GPR52

So I think one of the big opportunities that this study reveals is that there's actually a lot of known genes that, that are being presented as part of the findings that we had in this work.

So one of the big ones that we're really excited about is looking more into GPR52.

That's a gene that's associated with some of this Huntington's disease biology that we previously described and some of the other findings, uh, within the study, and there's already an investigational drug being used to treat Huntington's that acts through the GPR52 gene.

So what that means is that maybe some of what we're learning about fibromyalgia could be applied in the context of this GPR52 variant, and we might be able to use drugs that target GPR52 to help with fibromyalgia.

I don't know if that's necessarily gonna work, but I do think that hopefully we'll get to a point where we'll be able to understand better if it might.

So where do you go from here?

Well, I think definitely some of that work in, in GPR52 and some of our other target genes to say, like, are these going to improve care? Are there ways in which we could develop new drugs against some of the targets here? How can we think about the role of nociplastic pain in the development of fibromyalgia, or how people experience pain? I think all of those are important directions to look at.

And I think the other big direction that we should go in is trying to identify whether or not these risk factors are relevant for everybody with fibromyalgia, or maybe there's different subsets of people where some of these risk factors are more or less important.